Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 206 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: oral cannabinoid Clear all
Terminated Phase 2 Interventional

Sex Differences in Neurobehavioral Response to THC

NCT07225777
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

CBD Cannabis Extract: Pharmacokinetic Studies

NCT04280289
View directory record Official record
Conditions
Epilepsy
Interventions
cannabidiol extract
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance

NCT06218550
View directory record Official record
Conditions
Cannabis
Interventions
Delta-9-THC, Delta-8-THC, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 24, 2026, 1:30 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

NCT04883255
View directory record Official record
Conditions
HIV-1-infection
Interventions
10 mg Δ9-tetrahydrocannabinol (THC), 600 mg cannabidiol (CBD), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 1:30 AM EDT
Not listed Phase 2 Interventional

CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr

NCT04520685
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Oral cannabidiol 100mg/mL, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 17 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 24, 2026, 1:30 AM EDT
Recruiting Phase 1 Interventional

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

NCT06393101
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
BRC-002, BRC-002 Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 24, 2026, 1:30 AM EDT
Terminated Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

NCT03398837
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 24, 2026, 1:30 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I

NCT02811510
View directory record Official record
Conditions
Cannabis
Interventions
Placebo, Dronabinol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabidiol and Emotional Stimuli

NCT02902081
View directory record Official record
Conditions
Drug Addiction
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 24, 2026, 1:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

NCT01832766
View directory record Official record
Conditions
Schizophrenia
Interventions
Dronabinol, Placebo Comparator
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Oct 24, 2026, 1:30 AM EDT
Recruiting Phase 2 Interventional

Cannabidiol for Reducing Cigarette Use

NCT06218056
View directory record Official record
Conditions
Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence
Interventions
Cannabidiol (CBD) 800 mg, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
North Hollywood, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CBD, Immune Function, and Neural Health

NCT04881539
View directory record Official record
Conditions
Healthy
Interventions
Cannabidiol (CBD)
Dietary Supplement
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Greeley, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 24, 2026, 1:30 AM EDT
Not yet recruiting Phase 2 Interventional

nVNS, CBD, and SoC for Persistent Post-Traumatic Headache

NCT07624279
View directory record Official record
Conditions
Persistent Post Traumatic Headache
Interventions
Non-Invasive Vagus Nerve Stimulation, Cannabidiol, Standard of Care
Device · Drug
Lead sponsor
American Society of Pain and Neuroscience, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 1:30 AM EDT
Recruiting Phase 2 Interventional

Endocannabinoids in Reward

NCT07815691
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 45 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Phase 2 Interventional

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

NCT00642499
View directory record Official record
Conditions
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
36
States / cities
Bakersfield, California • Fresno, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 24, 2026, 1:30 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT03848832
View directory record Official record
Conditions
Rett Syndrome, RTT
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 24, 2026, 1:30 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

N-acetylcysteine Effects on Tetrahydrocannabinol

NCT02335060
View directory record Official record
Conditions
Healthy
Interventions
Delta-9-THC, N-acetylcysteine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Developing a Mobile Method to Measure THC-induced Impairment

NCT03804840
View directory record Official record
Conditions
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544750
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 24, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

CBD for Pain Following Orthopedic Shoulder Surgery

NCT06381791
View directory record Official record
Conditions
Shoulder Osteoarthritis, Rotator Cuff Injuries
Interventions
Epidiolex, Placebo oral solution
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 24, 2026, 1:30 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

NCT04517799
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Epidiolex, placebo oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 14 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)

NCT04760613
View directory record Official record
Conditions
Radiculopathy
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

NCT04754399
View directory record Official record
Conditions
Arthralgia, Breast Cancer
Interventions
Cannabidiol (CBD)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 24, 2026, 1:30 AM EDT